Thyroid dysfunction in patients treated with the immune checkpoint inhibitor nivolumab: different clinical features
Rationale. Immune Checkpoint Inhibitors (ICIs) are approved for some advanced neoplasms, increasing survival. ICIs block inhibitor receptors cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed death-1 (PD-1) and trigger T cell-mediated immunity against tumor. Their action is accompanied by sever...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Accademia Peloritana dei Pericolanti
2017-12-01
|
| Series: | Atti della Accademia Peloritana dei Pericolanti - Classe di Scienze Medico-Biologiche |
| Subjects: | |
| Online Access: | http://cab.unime.it/journals/index.php/APMB/article/view/1701 |